Insider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Buys $79,900.00 in Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) major shareholder Marlio Charles Mosseri bought 17,000 shares of the stock in a transaction on Friday, December 13th. The shares were acquired at an average cost of $4.70 per share, for a total transaction of $79,900.00. Following the purchase, the insider now owns 2,612,000 shares in the company, valued at approximately $12,276,400. This represents a 0.66 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Nuvectis Pharma Stock Performance

NVCT stock opened at $4.70 on Thursday. The firm has a 50 day simple moving average of $6.50 and a 200 day simple moving average of $6.54. Nuvectis Pharma, Inc. has a 52 week low of $4.48 and a 52 week high of $12.10. The stock has a market cap of $90.81 million, a P/E ratio of -4.05 and a beta of 0.20.

Nuvectis Pharma (NASDAQ:NVCT) last released its earnings results on Tuesday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. During the same quarter in the previous year, the company posted ($0.37) earnings per share. Sell-side analysts predict that Nuvectis Pharma, Inc. will post -1.01 EPS for the current year.

Institutional Trading of Nuvectis Pharma

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Nuvectis Pharma by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 298,800 shares of the company’s stock worth $2,450,000 after purchasing an additional 4,517 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Nuvectis Pharma by 20.7% in the 2nd quarter. Renaissance Technologies LLC now owns 74,500 shares of the company’s stock valued at $472,000 after buying an additional 12,800 shares in the last quarter. Nations Financial Group Inc. IA ADV bought a new stake in shares of Nuvectis Pharma in the 3rd quarter valued at approximately $63,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Nuvectis Pharma in the second quarter worth approximately $58,000. Finally, Geode Capital Management LLC raised its position in Nuvectis Pharma by 49.8% during the third quarter. Geode Capital Management LLC now owns 79,716 shares of the company’s stock valued at $501,000 after acquiring an additional 26,489 shares in the last quarter. Institutional investors and hedge funds own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.